Renal Cell Carcinoma

Lenvatinib in combination with pembrolizumab demonstrated clinical benefit in patients with advanced renal cell carcinoma regardless of their biomarker status.

Time to event end points and response rates were similar regardless of which first-line immunotherapy was administered, according to an analysis conducted by the International Metastatic Renal Cell Carcinoma Database Consortium

New data presented during the Genitourinary Cancers Symposium support the using cabozantinib after immunotherapy without new safety signals.

Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.

Cabozantinib administered in the neoadjuvant setting to patients with advanced renal cell carcinoma may be beneficial, but more research is needed to confirm.

Rana R. McKay, MD, discusses KEYNOTE-564 and the future of adjuvant immunotherapy in renal cell carcinoma.

In an interview with Targeted Oncology™, Naomi B. Haas, MD, discussed how the research has pivoted toward exploring neoadjuvant treatment for patients with renal cell carcinoma.

In an interview with Targeted Oncology, James Brugarolas, MD, PhD discussed promising updated survival data in metastatic renal cell carcinoma and investigational biomarkers to further advanced the field.

In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.

During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed the results of several major trials of drug combinations in patients with renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Sumanta Kumar Pal, David I. Quinn, MD, MBBS, PhD, and participants discussed frontline therapy options for a patient with metastatic relapsed/refractory renal cell carcinoma.

During a Targeted Oncology Case-Based Roundtable event, Toni K. Choueiri, MD, discussed treatment options using immune checkpoint inhibitors in patients with advanced renal cell carcinoma.

The target number of patients with advanced renal cell carcinoma has been enrolled in the phase 3 CONTACT-3 trial, which aims to determine the efficacy and safety of cabozantinib combined with atezolizumab.

In an interview with Targeted Oncology, Sunil Sudarshan, MD, discussed the kidney cancer paradigm and opportunities to advance the field with new targets.

During a live virtual event, Ulka Vaishampayan, MBBS, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab compared with sunitinib in first-line treatment of advanced RCC.

During a live virtual event, Sandy Srinivas, MD, discussed the tolerability of the tyrosine kinase inhibitor/immunotherapy combinations cabozantinib plus nivolumab and lenvatinib plus pembrolizumab, compared with the dual immunotherapy ipilimumab plus nivolumab.

Cristiane D. Bergerot, PhD, discusses how financial toxicity associated with renal cell carcinoma is impacting oncologists and their patients.

In an interview with Targeted Oncology, Matthew T. Campbell, MD, discussed unmet needs for patients with renal cell carcinoma and sarcomatoid dedifferentiation. He also explained how to approach the treatment of patients with challenging non-clear cell tumors.

In an interview with Targeted Oncology, Toni Choueiri, MD, discusses the impact the approval of adjuvant pembrolizumab has had on the RCC space.

Cristiane D. Bergerot, PhD, discussed factors contributing to financial toxicity in patients with RCC and how it impacts oncology care providers.

Toni Choueiri, MD, explains what led to the phase 3 COSMIC-313 clinical trial.

FDA approval is being sought for dovitinib as a treatment option for patients with renal cell carcinoma.